Related Experiment Videos
[Therapeutic value of humor]
1Servicio de Oncología Médica y Cuidados Paliativos. Hospital Universitario Marqués de Valdecilla. Facultad de Medicina. Universidad de Cantabria. Santander. España. oncsoj@humb.es
Medicina Clinica
|December 19, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Chemotherapy at the end of life: up until when?
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2012
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2009
Protein energy malnutrition (PEM) in cancer patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2008
Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2008
Oncologists' perceptions of cancer pain management in Spain: the real and the ideal.
European journal of pain (London, England)·2006
Foundations for the rational prescription of enteral medical nutrition therapy.
Medicina clinica·2026
Eating disorders.
Medicina clinica·2026
Finerenone for IgA Nephropathy After Renin-Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study.
Diabetes, obesity & metabolism·2026
Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [225Ac]Ac-DOTATATE therapy.
European journal of nuclear medicine and molecular imaging·2026
Naringenin alleviates age-related bone loss by targeting Runx2.
British journal of pharmacology·2026